Key facts
- It has raised $61.6M.
- Notable investors include SMBC Venture Capital, SBI Investment, StartX (US), Mizuho Capital, J-Startup — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Alivexis
- ·The full record, as it builds
Funding rounds
No funding rounds for Alivexis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alivexis
Developer of a drug discovery platform designed to accelerate the biotechnological research of new medicines. The company's platforms are prepared with computational drug discovery expertise and biology insights and focus on the rapid design and generation of small molecule clinical candidates for a range of high-value disease targets, enabling healthcare professionals to focus on the efficient delivery of medicines for patients and their families with unmet medical needs.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2017
- Employees
- 13
- Website
- alivexis.com/
- Ownership
- Privately Held (backing)
Alivexis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alivexis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alivexis in its N-PORT filings yet. We sweep new filings monthly.